|
||||||||||||||||||||||
|
|
Arimidex Neoadjuvant in Operable Breast Cancer in Post-Menopausal Women
Basic Trial Information
Summary To evaluate the efficacy, and safety of four months of treatment with anastrozole in an adjuvant setting, after that, conservative vs radical mastectomy clinical procedure is evaluated for next step surgical treatment, for post-menopausal women with hormonal receptors positive. Eligibility Criteria Inclusion Criteria:
Exclusion Criteria:
Trial Lead Organizations/Sponsors AstraZeneca Pharmaceuticals LP
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |